Drugs / human apotransferrin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03993613 | Mar 2019 → Mar 2022 | beta-thalassemia intermedia | Prothya Biosolutions | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human apotransferrin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03993613 ↗ |
| Action | Restore | “in order to restore the erythropoiesis” NCT03993613 ↗ |
| Modality | Protein / enzyme biologic | “Biological: human apotransferrin” NCT03993613 ↗ |
| Route | Intravenous | “Intravenous infusions” NCT03993613 ↗ |